BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 34326838)

  • 21. Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting.
    Bear AS; Blanchard T; Cesare J; Ford MJ; Richman LP; Xu C; Baroja ML; McCuaig S; Costeas C; Gabunia K; Scholler J; Posey AD; O'Hara MH; Smole A; Powell DJ; Garcia BA; Vonderheide RH; Linette GP; Carreno BM
    Nat Commun; 2021 Jul; 12(1):4365. PubMed ID: 34272369
    [TBL] [Abstract][Full Text] [Related]  

  • 22. G12V Kras mutations in cervical cancer under virtual microscope of molecular dynamics simulations.
    Chen XP; Xu WH; Xu DF; Fu SM; Ma ZC
    Eur J Gynaecol Oncol; 2016; 37(1):69-74. PubMed ID: 27048113
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Endogenous CD4
    Veatch JR; Jesernig BL; Kargl J; Fitzgibbon M; Lee SM; Baik C; Martins R; Houghton AM; Riddell SR
    Cancer Immunol Res; 2019 Jun; 7(6):910-922. PubMed ID: 31043415
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of HLA-A24-restricted CTL epitope from cancer-testis antigen, NY-ESO-1, and induction of a specific antitumor immune response.
    Yamaguchi H; Tanaka F; Ohta M; Inoue H; Mori M
    Clin Cancer Res; 2004 Feb; 10(3):890-6. PubMed ID: 14871964
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Systematic discovery and validation of T cell targets directed against oncogenic KRAS mutations.
    Choi J; Goulding SP; Conn BP; McGann CD; Dietze JL; Kohler J; Lenkala D; Boudot A; Rothenberg DA; Turcott PJ; Srouji JR; Foley KC; Rooney MS; van Buuren MM; Gaynor RB; Abelin JG; Addona TA; Juneja VR
    Cell Rep Methods; 2021 Sep; 1(5):100084. PubMed ID: 35474673
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Naproxen inhibits spontaneous lung adenocarcinoma formation in Kras
    Kumar G; Madka V; Singh A; Farooqui M; Stratton N; Lightfoot S; Mohammed A; Rao CV
    Neoplasia; 2021 Jun; 23(6):574-583. PubMed ID: 34091121
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HLA-A3 restricted mutant ras specific cytotoxic T-lymphocytes induced by vaccination with T-helper epitopes.
    Gjertsen MK; Saeterdal I; Saebøe-Larssen S; Gaudernack G
    J Mol Med (Berl); 2003 Jan; 81(1):43-50. PubMed ID: 12545248
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Processing and cross-presentation of individual HLA-A, -B, or -C epitopes from NY-ESO-1 or an HLA-A epitope for Melan-A differ according to the mode of antigen delivery.
    Robson NC; McAlpine T; Knights AJ; Schnurr M; Shin A; Chen W; Maraskovsky E; Cebon J
    Blood; 2010 Jul; 116(2):218-25. PubMed ID: 20430956
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Memory T cells of a patient with follicular thyroid carcinoma recognize peptides derived from mutated p21 ras (Gln-->Leu61).
    Gedde-Dahl T; Spurkland A; Eriksen JA; Thorsby E; Gaudernack G
    Int Immunol; 1992 Nov; 4(11):1331-7. PubMed ID: 1282032
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Proteasome-Generated
    Mansurkhodzhaev A; Barbosa CRR; Mishto M; Liepe J
    Front Immunol; 2021; 12():614276. PubMed ID: 33717099
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A census of predicted mutational epitopes suitable for immunologic cancer control.
    Warren RL; Holt RA
    Hum Immunol; 2010 Mar; 71(3):245-54. PubMed ID: 20035814
    [TBL] [Abstract][Full Text] [Related]  

  • 32. KRAS Genotype Correlates with Proteasome Inhibitor Ixazomib Activity in Preclinical In Vivo Models of Colon and Non-Small Cell Lung Cancer: Potential Role of Tumor Metabolism.
    Chattopadhyay N; Berger AJ; Koenig E; Bannerman B; Garnsey J; Bernard H; Hales P; Maldonado Lopez A; Yang Y; Donelan J; Jordan K; Tirrell S; Stringer B; Xia C; Hather G; Galvin K; Manfredi M; Rhodes N; Amidon B
    PLoS One; 2015; 10(12):e0144825. PubMed ID: 26709701
    [TBL] [Abstract][Full Text] [Related]  

  • 33.
    Miyamoto-Sato E; Imanishi S; Huang L; Itakura S; Iwasaki Y; Ishizaka M
    Molecules; 2023 Jul; 28(14):. PubMed ID: 37513471
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differences in gynecologic tumor development in Amhr2-Cre mice with KRAS
    Kun EHS; Tsang YTM; Lin S; Pan S; Medapalli T; Malpica A; Richards JS; Gershenson DM; Wong KK
    Sci Rep; 2020 Nov; 10(1):20678. PubMed ID: 33244099
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficient identification of novel HLA-A(*)0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis.
    Kessler JH; Beekman NJ; Bres-Vloemans SA; Verdijk P; van Veelen PA; Kloosterman-Joosten AM; Vissers DC; ten Bosch GJ; Kester MG; Sijts A; Wouter Drijfhout J; Ossendorp F; Offringa R; Melief CJ
    J Exp Med; 2001 Jan; 193(1):73-88. PubMed ID: 11136822
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In silico RNA-seq and experimental analyses reveal the differential expression and splicing of EPDR1 and ZNF518B genes in relation to KRAS mutations in colorectal cancer cells.
    Riffo-Campos ÁL; Castillo J; Vallet-Sánchez A; Ayala G; Cervantes A; López-Rodas G; Franco L
    Oncol Rep; 2016 Dec; 36(6):3627-3634. PubMed ID: 27805251
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Contribution of proteasome-catalyzed peptide
    Paes W; Leonov G; Partridge T; Chikata T; Murakoshi H; Frangou A; Brackenridge S; Nicastri A; Smith AG; Learn GH; Li Y; Parker R; Oka S; Pellegrino P; Williams I; Haynes BF; McMichael AJ; Shaw GM; Hahn BH; Takiguchi M; Ternette N; Borrow P
    Proc Natl Acad Sci U S A; 2019 Dec; 116(49):24748-24759. PubMed ID: 31748275
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analysis of the relationship between the KRAS G12V oncogene and the Hippo effector YAP1 in embryonal rhabdomyosarcoma.
    Mohamed AD; Shah N; Hettmer S; Vargesson N; Wackerhage H
    Sci Rep; 2018 Oct; 8(1):15674. PubMed ID: 30353028
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potential Mimicry of Viral and Pancreatic β Cell Antigens Through Non-Spliced and
    Mishto M; Mansurkhodzhaev A; Rodriguez-Calvo T; Liepe J
    Front Immunol; 2021; 12():656451. PubMed ID: 33936085
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The suppressive efficacy of THZ1 depends on KRAS mutation subtype and is associated with super-enhancer activity and the PI3K/AKT/mTOR signalling in pancreatic ductal adenocarcinoma: A hypothesis-generating study.
    Huang L; Yang H; Chen K; Yuan J; Li J; Dai G; Gu M; Shi Y
    Clin Transl Med; 2023 Dec; 13(12):e1500. PubMed ID: 38037549
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.